Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with
autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.